Literature DB >> 21557963

Chronic ibuprofen treatment does not affect the secondary pathology in the thalamus or improve behavioral outcome in middle cerebral artery occlusion rats.

Anu Lipsanen1, Mikko Hiltunen, Jukka Jolkkonen.   

Abstract

Anti-inflammatory drug ibuprofen decreases the β-amyloid (Aβ) deposition and associated inflammation in transgenic Alzheimer disease mice. Based on this, we studied whether ibuprofen could modulate the secondary pathology described in the thalamus of middle cerebral artery occlusion (MCAO) rats. Our hypothesis was that ibuprofen could decrease inflammatory reaction and Aβ load in the thalamus of MCAO rats, which in turn is reflected in improved behavioral outcome. Forty male Wistar rats (250-340 g) were subjected to sham-operation or transient occlusion of the right middle cerebral artery (120 min). Ibuprofen (4 0mg/kg/day, per os) was administrated for 27 days beginning the treatment on post-operative day 2. MCAO controls were given vehicle. Sensorimotor impairment was assessed using the limb-placing, tapered ledged beam-walking and cylinder tests during the follow-up. The rats were perfused for histology on postoperative day 29. Histological data showed that ibuprofen did not affect Aβ or calcium load in the thalamus of MCAO rats. In addition, behavioral tests did not show significant difference between vehicle- and ibuprofen-treated MCAO rats. The present data do not support the idea that ibuprofen reduces the secondary Aβ/calcium pathology in the thalamus or associated sensorimotor impairment following cerebral ischemia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557963     DOI: 10.1016/j.pbb.2011.04.019

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

Review 1.  Role of microglia in ischemic focal stroke and recovery: focus on Toll-like receptors.

Authors:  Jenni E Anttila; Keith W Whitaker; Emily S Wires; Brandon K Harvey; Mikko Airavaara
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-07-04       Impact factor: 5.067

Review 2.  Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?

Authors:  Fubing Ouyang; Zimu Jiang; Xinran Chen; Yicong Chen; Jiating Wei; Shihui Xing; Jian Zhang; Yuhua Fan; Jinsheng Zeng
Journal:  Transl Stroke Res       Date:  2021-06-30       Impact factor: 6.829

3.  Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg; Annette Theodorsson; Elvar Theodorsson
Journal:  BMC Neurosci       Date:  2013-04-01       Impact factor: 3.288

Review 4.  Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?

Authors:  Shannon M Stuckey; Lin Kooi Ong; Lyndsey E Collins-Praino; Renée J Turner
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

5.  Gait impairment in a rat model of focal cerebral ischemia.

Authors:  Saara Parkkinen; Francisco J Ortega; Kristina Kuptsova; Joanna Huttunen; Ina Tarkka; Jukka Jolkkonen
Journal:  Stroke Res Treat       Date:  2013-03-03

6.  Non-selective calcium channel blocker bepridil decreases secondary pathology in mice after photothrombotic cortical lesion.

Authors:  Anu Lipsanen; Stefanie Flunkert; Kristina Kuptsova; Mikko Hiltunen; Manfred Windisch; Birgit Hutter-Paier; Jukka Jolkkonen
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.